Tags

Type your tag names separated by a space and hit enter

Beyond BMI: The "Metabolically healthy obese" phenotype & its association with clinical/subclinical cardiovascular disease and all-cause mortality -- a systematic review.
BMC Public Health. 2014 Jan 08; 14:14.BP

Abstract

BACKGROUND

A subgroup has emerged within the obese that do not display the typical metabolic disorders associated with obesity and are hypothesized to have lower risk of complications. The purpose of this review was to analyze the literature which has examined the burden of cardiovascular disease (CVD) and all-cause mortality in the metabolically healthy obese (MHO) population.

METHODS

Pubmed, Cochrane Library, and Web of Science were searched from their inception until December 2012. Studies were included which clearly defined the MHO group (using either insulin sensitivity and/or components of metabolic syndrome AND obesity) and its association with either all cause mortality, CVD mortality, incident CVD, and/or subclinical CVD.

RESULTS

A total of 20 studies were identified; 15 cohort and 5 cross-sectional. Eight studies used the NCEP Adult Treatment Panel III definition of metabolic syndrome to define "metabolically healthy", while another nine used insulin resistance. Seven studies assessed all-cause mortality, seven assessed CVD mortality, and nine assessed incident CVD. MHO was found to be significantly associated with all-cause mortality in two studies (30%), CVD mortality in one study (14%), and incident CVD in three studies (33%). Of the six studies which examined subclinical disease, four (67%) showed significantly higher mean common carotid artery intima media thickness (CCA-IMT), coronary artery calcium (CAC), or other subclinical CVD markers in the MHO as compared to their MHNW counterparts.

CONCLUSIONS

MHO is an important, emerging phenotype with a CVD risk between healthy, normal weight and unhealthy, obese individuals. Successful work towards a universally accepted definition of MHO would improve (and simplify) future studies and aid inter-study comparisons. Usefulness of a definition inclusive of insulin sensitivity and stricter criteria for metabolic syndrome components as well as the potential addition of markers of fatty liver and inflammation should be explored. Clinicians should be hesitant to reassure patients that the metabolically benign phenotype is safe, as increased risk cardiovascular disease and death have been shown.

Authors+Show Affiliations

No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableCenter for Prevention and Wellness Research, Baptist Health Medical Group, Michigan Ave Suite 500, Miami Beach, Florida. Khurramn@baptisthealth.net.

Pub Type(s)

Journal Article
Review
Systematic Review

Language

eng

PubMed ID

24400816

Citation

Roberson, Lara L., et al. "Beyond BMI: the "Metabolically Healthy Obese" Phenotype & Its Association With Clinical/subclinical Cardiovascular Disease and All-cause Mortality -- a Systematic Review." BMC Public Health, vol. 14, 2014, p. 14.
Roberson LL, Aneni EC, Maziak W, et al. Beyond BMI: The "Metabolically healthy obese" phenotype & its association with clinical/subclinical cardiovascular disease and all-cause mortality -- a systematic review. BMC Public Health. 2014;14:14.
Roberson, L. L., Aneni, E. C., Maziak, W., Agatston, A., Feldman, T., Rouseff, M., Tran, T., Blaha, M. J., Santos, R. D., Sposito, A., Al-Mallah, M. H., Blankstein, R., Budoff, M. J., & Nasir, K. (2014). Beyond BMI: The "Metabolically healthy obese" phenotype & its association with clinical/subclinical cardiovascular disease and all-cause mortality -- a systematic review. BMC Public Health, 14, 14. https://doi.org/10.1186/1471-2458-14-14
Roberson LL, et al. Beyond BMI: the "Metabolically Healthy Obese" Phenotype & Its Association With Clinical/subclinical Cardiovascular Disease and All-cause Mortality -- a Systematic Review. BMC Public Health. 2014 Jan 8;14:14. PubMed PMID: 24400816.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Beyond BMI: The "Metabolically healthy obese" phenotype & its association with clinical/subclinical cardiovascular disease and all-cause mortality -- a systematic review. AU - Roberson,Lara L, AU - Aneni,Ehimen C, AU - Maziak,Wasim, AU - Agatston,Arthur, AU - Feldman,Theodore, AU - Rouseff,Maribeth, AU - Tran,Thinh, AU - Blaha,Michael J, AU - Santos,Raul D, AU - Sposito,Andrei, AU - Al-Mallah,Mouaz H, AU - Blankstein,Ron, AU - Budoff,Matthew J, AU - Nasir,Khurram, Y1 - 2014/01/08/ PY - 2013/06/25/received PY - 2013/12/10/accepted PY - 2014/1/10/entrez PY - 2014/1/10/pubmed PY - 2015/8/19/medline SP - 14 EP - 14 JF - BMC public health JO - BMC Public Health VL - 14 N2 - BACKGROUND: A subgroup has emerged within the obese that do not display the typical metabolic disorders associated with obesity and are hypothesized to have lower risk of complications. The purpose of this review was to analyze the literature which has examined the burden of cardiovascular disease (CVD) and all-cause mortality in the metabolically healthy obese (MHO) population. METHODS: Pubmed, Cochrane Library, and Web of Science were searched from their inception until December 2012. Studies were included which clearly defined the MHO group (using either insulin sensitivity and/or components of metabolic syndrome AND obesity) and its association with either all cause mortality, CVD mortality, incident CVD, and/or subclinical CVD. RESULTS: A total of 20 studies were identified; 15 cohort and 5 cross-sectional. Eight studies used the NCEP Adult Treatment Panel III definition of metabolic syndrome to define "metabolically healthy", while another nine used insulin resistance. Seven studies assessed all-cause mortality, seven assessed CVD mortality, and nine assessed incident CVD. MHO was found to be significantly associated with all-cause mortality in two studies (30%), CVD mortality in one study (14%), and incident CVD in three studies (33%). Of the six studies which examined subclinical disease, four (67%) showed significantly higher mean common carotid artery intima media thickness (CCA-IMT), coronary artery calcium (CAC), or other subclinical CVD markers in the MHO as compared to their MHNW counterparts. CONCLUSIONS: MHO is an important, emerging phenotype with a CVD risk between healthy, normal weight and unhealthy, obese individuals. Successful work towards a universally accepted definition of MHO would improve (and simplify) future studies and aid inter-study comparisons. Usefulness of a definition inclusive of insulin sensitivity and stricter criteria for metabolic syndrome components as well as the potential addition of markers of fatty liver and inflammation should be explored. Clinicians should be hesitant to reassure patients that the metabolically benign phenotype is safe, as increased risk cardiovascular disease and death have been shown. SN - 1471-2458 UR - https://www.unboundmedicine.com/medline/citation/24400816/Beyond_BMI:_The_"Metabolically_healthy_obese"_phenotype_&_its_association_with_clinical/subclinical_cardiovascular_disease_and_all_cause_mortality____a_systematic_review_ L2 - https://bmcpublichealth.biomedcentral.com/articles/10.1186/1471-2458-14-14 DB - PRIME DP - Unbound Medicine ER -